Man Group PLC Vaxcyte, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Man Group PLC holds 14,551 shares of PCVX stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,551

Holding current value

$1.25 Million

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $1.03 Million - $1.7 Million	14,551 New	14,551 $1.66 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $924,594 - $1.2 Million	25,492 New	25,492 $955,000

Others Institutions Holding PCVX

# of Institutions

353

Shares Held

122M

Call Options Held

775K

Put Options Held

433K

Vanguard Group Inc Valley Forge, PA

11.4M
Shares

$986 Million
0.02% of portfolio
Janus Henderson Group PLC London, X0

10.9M
Shares

$942 Million
0.67% of portfolio
Black Rock Inc. New York, NY

9.94M
Shares

$857 Million
0.02% of portfolio
Ra Capital Management, L.P. Boston, MA

8.69M
Shares

$749 Million
13.83% of portfolio
Capital Research Global Investors Los Angeles, CA

4.9M
Shares

$422 Million
0.12% of portfolio

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.11B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account